1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. PI5P4K
  4. PI5P4K Inhibitor

PI5P4K Inhibitor

PI5P4K Inhibitors (15):

Cat. No. Product Name Effect Purity
  • HY-139868
    BAY-091
    Inhibitor 99.55%
    BAY-091 is a novel potent and highly selective inhibitor of the kinase PIP4K2A.
  • HY-136311
    NCT-504
    Inhibitor 98.70%
    NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC50 of 15.8 μM. NCT-504 is potential for the research of Huntington's disease.
  • HY-136310
    PIP4K-IN-a131
    Inhibitor 98.92%
    PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC50s of 1.9?μM and 0.6?μM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways.
  • HY-139188
    CC260
    Inhibitor 99.21%
    CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with Kis of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research.
  • HY-101423
    NIH-12848
    Inhibitor 99.84%
    NIH-12848 is a putative phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) inhibitor with an IC50 of 1 μM.
  • HY-153531
    PI5P4Kα-IN-1
    Inhibitor 98.49%
    PI5P4Kα-IN-1 (Compound 13) is a PI5P4Kinhibitor (IC50: 2 and 9.4 μM for PI5P4Kα and PI5P4Kβ). PI5P4Kα-IN-1 can be used for research of cancer, metabolic and immunological disorders.
  • HY-149659
    ARUK2007145
    Inhibitor 98.16%
    ARUK2007145 is potent, cell-active dual inhibitor of the PI5P4Kα and PI5P4Kγ isoforms (pIC50: 7.3 and 8.1, respectively).
  • HY-152155
    ARUK2001607
    Inhibitor 99.73%
    ARUK2001607 is a selective phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) inhibitor with a Kd of 7.1 nM. ARUK2001607 shows high selectivity over other >150 kinases.
  • HY-153789
    PI5P4Kγ-IN-1
    Inhibitor
    PI5P4Kγ-IN-1 (compound 2) is a selective PI5P4Kγ inhibitor. PI5P4Kγ-IN-1 can be used to signal mTORC1 in MCF-7 breast cancer cells and further characterize PI5P4Kγ in the cells.
  • HY-153526
    PI5P4Ks-IN-2
    Inhibitor 99.78%
    PI5P4Ks-IN-2 is a inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ). PI5P4Ks-IN-2 targets to PI5P4K isoforms with pIC50 values of <4.3 (PI5P4Kα), <4.6 (PI5P4Kβ), 6.2 (PI5P4Kγ), 0.32 (PI5P4Kγ+), respectively.
  • HY-145689
    PI5P4Ks-IN-1
    Inhibitor
    PI5P4Ks-IN-1 (compound 7) is an active compound with no detectable inhibition of the PI5P4K α or β isoforms.
  • HY-153532
    CVM-05-002
    Inhibitor
    CVM-05-002 is a PI5P4K inhibitor, with IC50 values of 0.27 μM and 1.7 μM for PI5P4Kα and PI5P4Kβ, respectively.
  • HY-149423
    PI5P4K-β-IN-1
    Inhibitor
    PI5P4K-β-IN-1 (compound vs1) is a potent inhibitor of PI5P4K-β (IC50: 0.80 μM).
  • HY-153529
    PI5P4Ks-IN-3
    Inhibitor
    PI5P4Ks-IN-3 (compound 30) is a covalent inhibitor of PI5P4K with IC50s of 1.34 μM (PI5P4Kα),and 9.9 μM (PI5P4Kβ),respectively. PI5P4Ks-IN-3 shows weak cellular activity.
  • HY-149424
    PI5P4K-β-IN-2
    Inhibitor
    PI5P4K-β-IN-2 (compound d5) is a PI5P4K-β inhibitor (IC50=0.35 μM) with antitumor activity.